Gustavo M. Gryzinski

Gustavo M. Gryzinski

Auto-generated profile, based on publicly available information

Gustavo M. Gryzinski

University of California, Irvine Department of Urology, Irvine, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
JFJason M. Farrow
Jason M. Farrow
SKSean Kern
Sean Kern
GGGustavo M. Gryzinski
Gustavo M. Gryzinski
CSChandru P. Sundaram
Chandru P. Sundaram
Urothelial carcinoma of the upper urinary tract is uncommon and presents unique challenges for diagnosis and management. Nephroureterectomy has been the preferred management option, but it is associated with significant morbidity. Nephron-sparing treatments are a valuable alternative and provide similar efficacy in select cases. A PubMed literature review was performed in English language publications using the following search terms: urothelial carcinoma, upper tract, nephron-sparing, intraluminal and systemic therapy. Contemporary papers published within the last 10 years were primarily included. Where encountered, systematic reviews and meta-analyses were given priority, as were randomized controlled trials for newer treatments. Core guidelines were referenced and citations reviewed for inclusion. A summary of epidemiological data, clinical diagnosis, staging, and treatments focusing on nephron-sparing approaches to upper tract urothelial carcinoma (UTUC) are outlined. Nephron-sparing management strategies are viable options to consider in patients with favorable features of UTUC. Adjunctive therapies are being investigated but the data remains mixed. Protocol variability and dosage differences limit statistical interpretation. New mechanisms to improve treatment dwell times in the upper tracts are being designed with promising preliminary results. Studies investigating systemic therapies are ongoing but implications for nephron-sparing management are uncertain. Nephron-sparing management is an acceptable treatment modality best suited for favorable disease. More work is needed to determine if intraluminal and/or systemic therapies can further optimize treatment outcomes beyond resection alone.

7 April 2022 in International Journal Of Impotence Research
Verified
Journal Article
Closed access
PDF file
GGGustavo M. Gryzinski
Gustavo M. Gryzinski
HBHelen L. Bernie
Helen L. Bernie

19 June 2024 in International Journal Of Impotence Research
Verified
Journal Article
Open access
PDF file
GGGustavo Gryzinski
Gustavo Gryzinski
MHMuhammed A Moukhtar Hammad
Muhammed A Moukhtar Hammad
LALaith Alzweri
Laith Alzweri
BABabak Azad
Babak Azad
DBDavid Barham
David Barham
FYFaysal Yafi
Faysal Yafi
Hard-flaccid syndrome (HFS) is a poorly understood condition of male sexual dysfunction (MSD) that has more recently become a new topic of discussion in online forums and sexual medicine conferences. There has been limited research looking into HFS and consequently there are no evidence-based guidelines for its work-up and management. In order to identify the current level of understanding of HFS in the sexual medicine community, a survey was distributed at a national urologic conference focusing on pertinent management strategies employed by practitioners, and their own thoughts on HFS. This showed that nearly one-third of those surveyed had never seen HFS in their practice. Of those that had, diagnosis was mainly made via clinical history as well as patient self-diagnosis. Additionally, only about half of the respondents who had seen HFS were confident in its legitimacy as a real medical syndrome. This analysis is one of the first of its kind, and highlights the ongoing lack of familiarity of HFS among the sexual medicine community. There were limitations, most notably its survey format as well as low sample size, however, it importantly emphasizes the critical need for continued education and research into HFS to improve diagnostic accuracy, enhance patient care, and develop effective treatment strategies.

1 October 2022 in Androgens: Clinical Research and Therapeutics
Verified
Journal Article
Open access
GGGustavo M. Gryzinski
Gustavo M. Gryzinski
JFJudy Fustok
Judy Fustok
OROmer A. Raheem
Omer A. Raheem
HBHelen L. Bernie
Helen L. Bernie
With an increase in the use of androgen deprivation therapy (ADT) in men diagnosed with prostate cancer, there are several adverse effects that accompany its utilization. Among these, sexual dysfunction has contributed to significant deleterious effects on quality of life (QoL) and overall satisfaction. This has prompted clinicians to pursue modalities of ADT that may mitigate these adverse sexual effects, which include continuous versus intermittent ADT, changes in the duration of ADT, and novel methods of cyclical androgen exposure during treatment. Importantly, this must not come at the expense of oncological outcomes. In addition, some men treated with ADT experience persistent hypogonadism and side effects from these medications that linger well after treatment is completed. In this systematic review we discuss the pharmaceutical, mechanical, and psychological methods that play an important role in the mitigation of these sexual side effects, including erectile dysfunction and decreased libido, and their uses and benefits are further discussed. Ultimately, the benefits of ADT and the possible morbidity that these men may experience from use of ADT, as well as options to minimize their side effects need to be discussed with the patient and their partner to make an informed decision and ensure patient autonomy while providing the most up-to-date evidence. Given the prevalence of prostate cancer in the aging male population, this systematic review aims to further explain the different ADT regimens and options for men, as well as discuss the sexual side effects that accompany these treatments and ways in which to mitigate these side effects to improve patient QoL.

1 June 2023 in Journal of Urology
Verified
Journal Article
Closed access
GGGustavo M. Gryzinski
Gustavo M. Gryzinski
MHMuhammed A Moukhtar Hammad
Muhammed A Moukhtar Hammad
DBDavid W. Barham
David W. Barham
FYFaysal A. Yafi
Faysal A. Yafi